| Dr Henry Allen Hooper, MD | |
|
1600 N Rose Ave, Oxnard, CA 93030-3722 | |
| (805) 988-2674 | |
| (805) 981-4443 |
| Full Name | Dr Henry Allen Hooper |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1600 N Rose Ave, Oxnard, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932155223 | NPI | - | NPPES |
| 00G300540 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G30054 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
A new imaging technique to track maternal blood flow to the placenta has the potential to help diagnose several common complications in early pregnancy, according to a study funded by the National Institutes of Health.
Adolescents discharged from hospitals in England after an admission for violent, drug- or alcohol-related, or self-inflicted injuries have increased risks of subsequent death and emergency re-admission up to a decade later, according to a study published this week in PLOS Medicine.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
› Verified 5 days ago
| Entity Name | Pinnacle Emergency Physicians Of Bakersfield, A Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619153251 PECOS PAC ID: 7214086321 Enrollment ID: O20090520000375 |
News Archive
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
A new imaging technique to track maternal blood flow to the placenta has the potential to help diagnose several common complications in early pregnancy, according to a study funded by the National Institutes of Health.
Adolescents discharged from hospitals in England after an admission for violent, drug- or alcohol-related, or self-inflicted injuries have increased risks of subsequent death and emergency re-admission up to a decade later, according to a study published this week in PLOS Medicine.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Henry Allen Hooper, MD 1601 Cummins Dr. Suite D, Modesto, CA 95358-6403 Ph: (209) 491-7710 | Dr Henry Allen Hooper, MD 1600 N Rose Ave, Oxnard, CA 93030-3722 Ph: (805) 988-2674 |
News Archive
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
A new imaging technique to track maternal blood flow to the placenta has the potential to help diagnose several common complications in early pregnancy, according to a study funded by the National Institutes of Health.
Adolescents discharged from hospitals in England after an admission for violent, drug- or alcohol-related, or self-inflicted injuries have increased risks of subsequent death and emergency re-admission up to a decade later, according to a study published this week in PLOS Medicine.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
› Verified 5 days ago
Christine Chang, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2663 | |
Dr. Van Anh Chandler, MEDICAL DOCTOR Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2674 | |
Dr. John Wordy Buckner Iv, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2500 | |
Dr. Patrick Um, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2679 | |
Dr. Shon Marcos Sidransky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2843 Fax: 805-988-2844 | |
Dr. Richard E.m. Wagner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2843 Fax: 805-988-2844 | |
Dr. Richard F. Handin, MEDICAL DOCTOR Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 N Rose Ave, Oxnard, CA 93030 Phone: 805-988-2674 Fax: 805-969-5878 |